These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 39181430)
1. Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Clark LJ; Jafry Z; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS Clin Gastroenterol Hepatol; 2024 Aug; ():. PubMed ID: 39181430 [TBL] [Abstract][Full Text] [Related]
2. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567 [TBL] [Abstract][Full Text] [Related]
3. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. Choi WM; Kim GA; Choi J; Han S; Lim YS J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094 [TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients. Choi WM; Yip TC; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Clark LJ; Jafry Z; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Wong GL; Lim YS Hepatology; 2024 Aug; 80(2):428-439. PubMed ID: 38436992 [TBL] [Abstract][Full Text] [Related]
5. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic Model. Kim GA; Lim YS; Han S; Choi GH; Choi WM; Choi J; Sinn DH; Paik YH; Lee JH; Lee YB; Cho JY; Heo NY; Yuen MF; Wong VW; Chan SL; Yang HI; Chen CJ Ann Intern Med; 2024 Oct; 177(10):1308-1318. PubMed ID: 39284185 [TBL] [Abstract][Full Text] [Related]
6. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683 [TBL] [Abstract][Full Text] [Related]
7. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Kim GA; Han S; Choi GH; Choi J; Lim YS Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment. Li J; Dong XQ; Cao LH; Zhang ZQ; Zhao WF; Shang QH; Zhang DZ; Ma AL; Xie Q; Gui HL; Zhang G; Liu YX; Shang J; Xie SB; Liu YQ; Zhang C; Wang GQ; Zhao H; Front Cell Infect Microbiol; 2023; 13():1151899. PubMed ID: 37396307 [TBL] [Abstract][Full Text] [Related]
9. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. Yuan Y; Iloeje UH; Hay J; Saab S J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879 [TBL] [Abstract][Full Text] [Related]
12. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma. Yang Z; Cheung RC; Jou JH; Lim JK; Lim YS; Wong RJ Gastroenterology Res; 2024 Jun; 17(3):109-115. PubMed ID: 38993547 [TBL] [Abstract][Full Text] [Related]
13. What can we learn from hepatitis B virus clinical cohorts? Lin CL; Tseng TC; Kao JH Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093 [TBL] [Abstract][Full Text] [Related]
14. [Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load]. Deng DL; Jiang JN; Su MH; Wang RM; Zang WW; Ling XZ; Wei HL; Liang XS; Zhou HK; He WM; Guo RS Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1013-1017. PubMed ID: 34865348 [No Abstract] [Full Text] [Related]
15. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870 [TBL] [Abstract][Full Text] [Related]
16. Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B. Kim GA; Choi SW; Han S; Lim YS Clin Mol Hepatol; 2024 Oct; 30(4):793-806. PubMed ID: 39026397 [TBL] [Abstract][Full Text] [Related]
17. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B. Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047 [TBL] [Abstract][Full Text] [Related]
18. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Jang H; Yoon JS; Park SY; Lee HA; Jang MJ; Kim SU; Sinn DH; Seo YS; Kim HY; Kim SE; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Nam JY; Lee YB; Kim YJ; Yoon JH; Zoulim F; Lampertico P; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen H; Papatheodoridis GV; Lee JH Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1343-1353.e16. PubMed ID: 34500103 [TBL] [Abstract][Full Text] [Related]
19. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Wongjarupong N; Yonli AT; Nagalo BM; Djigma FW; Somda SK; Hassan MA; Mohamed EA; Sorgho AP; Compaore TR; Soubeiga ST; Kiendrebeogo I; Sanou M; Diarra B; Yang HI; Chen CJ; Ouattara AK; Zohoncon TM; Martinson JJ; Buetow K; Chamcheu JC; Antwi SO; Borad MJ; Simpore J; Roberts LR Hepatol Commun; 2020 Dec; 4(12):1781-1792. PubMed ID: 33305149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]